On  Sep 8, 2010  mBeach Software Inc (MBHS.PK) announced plans to redefine the activities of MBHS and Skin Cancer Scanning Ltd. (SCS). This follows the July 15 announcement of the closure of the merger with SCS, as a result of which MBHS holds 100% of SCS.

Skin Cancer Scanning Ltd. (SCS) is a medical device company focused on developing and marketing a non-invasive, painless test that can be completed quickly in the doctor’s office. Its objective is to improve early detection and more accurately diagnose skin cancer and precancerous lesions.

Our management team has the proven entrepreneurial, managerial, and technical skills and experience to succeed in expanding this innovative company. As the business grows, we will recruit additional experienced professionals to complement the management team.

Professor Nathan Blaunstein, MSc, DSc, PhD., Scientific Advisory Board Member

Professor Blaunstein is Professor of the Department of Information Systems Engineering, at Ben-Gurion University, Israel. Blaunstein is a recognized expert in Wireless Cellular. He is also  a recognized expert in radio wave propagation, diffraction. Prof. Blaunstein has authored more than ten books and over 150 articles in scientific journals, and conference papers. He has also [...]

Read more

Col. Yossi Biderman, CEO

Mr. Biderman brings 34 years of command and managerial experience. 22 years with the Israel Defense Forces in command of field units. Retired regular service as Brigade commander. 12 years in executive positions as business development manager, CEO of financial advisory company. Col. Biderman brings experience in the commodity market in large organizations. He has [...]

Read more

Mr. Bunim Brimer, MSc., Director

A Senior Executive, Mr. Brimer brings with him 22 years of developing international markets in the highly competitive field of Perimeter security. Mr. Brimer holds the position of head of the projects division operating in the field of perimeter protection systems; in the Magal group Ltd., a publicly traded Company on the Tel Aviv Stock [...]

Read more

Mr. Alex Blaunstein, Director

An experienced executive Mr. Blaunstein was a marketing consultant for Arkia International  airlines. Mr. Blaunstein has served in the public service, as an advisor to a Parliament Member (MK) active and consulting  in legislation issues, public relations and public complaints. For the past four years Mr. Blaunstein has held the position of President of an [...]

Read more

Dr.Yafim Smolyak, Ph.D, Scientific Expert

Dr. Smolak is an expert in infra-red technologies. He brings over twenty years R&D experience in optical devices, fiber optic communications, and optical measurement and testing. Dr. Smolak has registered three patents and has authored more than 15 articles on optical systems.

Read more

Corporate Governance

We are committed to being responsible corporate citizens. And as such, we will always consider the interests of society by taking responsibility for the impact of our activities on customers, employees, shareholders, communities and the environment in all aspects of our operations. For us, this is more than a statutory obligation to comply with legislation. Rather, we view this as our voluntary commitment to have a positive impact on our stakeholders and our world.

We have established a series of formalized processes, policies and laws defining the way in which our organization is directed, administered or controlled.
Skin Cancer Scanning (SCS) Ltd. is a publicly traded company (symbol: MBHS).

We have chosen to run all our operations under the strictest guide rules and regulations of the European ISO 9000 management quality standard and the ISO 13845 European medical device producers standards.

• We are committed to providing our customers with our best possible efforts.

• We are committed to establishing and maintaining sound relationships with our other stakeholder groups such as our shareholders, employees, suppliers, business associates, and last but not least, the community-at-large.

• We acknowledge and accept our accountability and fiduciary duty, and we will act with the best intent to protect our stakeholder groups. 

• We will work to optimize our economic results – for our shareholders as well as our clients.

• We will behave as responsible members of the community-at-large, participating in our local communities and protecting our global environment.

Skin Cancer Scanning Ltd. (SCS) is a medical device company focused on developing and marketing a non-invasive, painless test that can be completed quickly in the doctor’s office. Our objective is to improve early detection and more accurately diagnose skin cancer and precancerous lesions.

Our early detection device, SkinScan 650, enables physicians to improve their diagnostic abilities using state-of-the-art technology. This replaces current diagnostic procedures that have many disadvantages, such as being relatively subjective and dependent on the experience of the examiner. Errors in diagnosis can be fatal. Cancers can remain undetected, grow further and reduce to chances of survival. A biopsy, the intrusive removal of tissue sample, is usually needed for further diagnoses.

SkinScan 650 provides a clear value proposition, both to the patient and healthcare system:

• Diagnoses cancerous lesions on the spot. Diagnosing cancer at an early stage enables a greater opportunity to cure and lower treatment costs.

• Reduces the number of referrals for biopsies. This has many clear disadvantages:

• Less scarring: A biopsy can result in cosmetic scarring

• Less pain: Biopsies require intrusive removal of tissue that can be painful and expensive

• Less patient anxiety: There is a time lag between the examination and the biopsy results. This increases costs, inconvenience to the patient, and the risk the disease will reach a point where it is harder to treat. In addition, this waiting period causes significant anxiety to the patient.

 

So far we have successfully completed two stages of clinical trials at the Rabin Medical Center in Petah Tikva, Israel. We plan to soon launch SkinScan 650 commercially in major world markets.

Patents Pending

Patent applicants have been submitted in both the US (Patent pending 11/464,838) and worldwide under the PCT framework (PCT/IL2006/000954).